Medical Access Program for Patritumab Deruxtecan
Public ClinicalTrials.gov record NCT06099639. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Medical Access Program for Patritumab Deruxtecan (HER3 DXd, U3-1402)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this Medical Access Program is to provide access to HER3-DXd for eligible patients with NSCLC who, in their treating physician's opinion, have an unmet clinical need which cannot be treated with approved and commercially available drugs and who cannot enter a clinical trial prior to commercial availability.
Study identification
- NCT ID
- NCT06099639
- Recruitment status
- No Longer Available
- Study type
- Expanded access
- Phase
- Not listed
- Enrollment
- Not listed
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Jun 8, 2025
United States locations
- U.S. sites
- 21
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology | Springdale | Arkansas | 72762 | — |
| Southern California Permanente Medical Group | Los Angeles | California | 91101 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Yale-New Haven Hospital | New Haven | Connecticut | 06510 | — |
| Advent Health | Orlando | Florida | 32804 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Block Medical Center | Skokie | Illinois | 60077 | — |
| Baptist Health Lexington | Lexington | Kentucky | 40503 | — |
| Karmanos Cancer Institute (Barbara Ann Karmanos Cancer Hospital) | Detroit | Michigan | 48201 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| The Washington University | St Louis | Missouri | 63130 | — |
| Overlook Medical Center | Summit | New Jersey | 07901 | — |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14263 | — |
| Kettering Health Cancer Center | New York | New York | 10029 | — |
| The Mount Sinai Hospital- (Icahn School of Medicine) | New York | New York | 10029 | — |
| Messino Cancer Center | Asheville | North Carolina | 28806 | — |
| Duke Cancer Institute | Durham | North Carolina | 27710 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| The Kaiser Permanente Medical Group | Portland | Oregon | 97227 | — |
| Texas Oncology | Pearland | Texas | 77584 | — |
| Peace Health | Bellingham | Washington | 98225 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06099639, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 8, 2025 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06099639 live on ClinicalTrials.gov.